Suzlon Energy shares fell 4.76% on January 28, ahead of the company’s Q3 FY25 results announcement. Despite a strong Q2 performance with a 96% YoY profit increase, the stock has struggled recently, down 24.10% in the past month and 26.54% YTD. Analyst sentiment remains positive, with a consensus ‘buy’ rating on the stock.
Biocon buys back an investor stake in biologics unit, posts Rs 25 crore net profit in Q3FY25
Biocon’s board has approved the acquisition of 1.5% equity in Biocon Biologics for Rs 550 crore, increasing its stake to 90.2%. The deal is expected
January 30, 2025